Status: Not yet recruiting
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
This study aims to evaluate the efficacy and safety of Romiplostim N01 for Injection administered as secondary prophylaxis in breast cancer patients with chemotherapy-induced thrombocytopenia (CIT).
Participants needed: 53
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Aug 18, 2026Locations: 1
Eligibility criteria
Signed informed consent form. [+8]
Concomitant hematologic disorders; [+13]